Year: 2021

Test Material from Large Scale Production Approved

The first batch of test material from the large-scale production of Nanologica AB’s silica has been approved. The quality of the material produced at the CMO Sterling Pharma Solutions in the UK is identical to the material produced at Nanologica’s plant in Södertälje. In December 2020, the first batch of test material from the upscaling to large-scale production of Nanologica’s silica was delivered. Rigorous quality testing of the silica now confirms identical quality to the

Read more »

Nanologica Engages Scientific Advisors within Inhalation

Nanologica AB has engaged two senior scientific advisors within the field of respiratory drug delivery, for the purpose of advancing the NLAB Spiro™ inhalation platform further. Dr. John Pritchard has more than 40 years of experience from the inhalation industry working in various positions, leading and managing global portfolios of technology projects from discovery to market, at for example GlaxoSmithKline, 3M Health Care Ltd and as Head of Respiratory Project Management at AstraZeneca. His vast

Read more »

Nanologica ändrar datum för publicering av bokslutskommuniké 2020

Nanologicas bokslutskommuniké kommer att publiceras fredagen den 26 februari, istället för den 19 februari som tidigare meddelats. Datum för kommande finansiella rapporter: Bokslutskommuniké 2020                           26 februari, 2021 Årsredovisning 2020                                     23 april, 2021 Delårsrapport jan-mar 2021                        7 maj, 2021   För ytterligare information, vänligen kontakta: Johanna Johansson,

Read more »